The Pharmacokinetic and Pharmacodynamic Properties of Hydroxychloroquine and Dose Selection for COVID-19: Putting the Ca
- PDF / 372,014 Bytes
- 12 Pages / 595.276 x 790.866 pts Page_size
- 42 Downloads / 137 Views
REVIEW
The Pharmacokinetic and Pharmacodynamic Properties of Hydroxychloroquine and Dose Selection for COVID-19: Putting the Cart Before the Horse Taylor Morrisette . Thomas P. Lodise . Marc H. Scheetz . Srijib Goswami . Jason M. Pogue . Michael J. Rybak
Received: June 22, 2020 The Author(s) 2020
ABSTRACT Coronavirus disease 2019 (COVID-19), caused by the 2019 novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is currently responsible for a global pandemic. To date, only remdesivir and dexamethasone have demonstrated a positive response in a prospective,
Digital Features To view digital features for this article go to https://doi.org/10.6084/m9.figshare.12689780. T. Morrisette M. J. Rybak (&) Anti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI, USA e-mail: [email protected] T. P. Lodise Albany College of Pharmacy and Health Sciences, Albany, NY, USA M. H. Scheetz Department of Pharmacy Practice, Chicago College of Pharmacy, Midwestern University, Downers Grove, IL, USA M. H. Scheetz Pharmacometrics Center of Excellence, Midwestern University, Downers Grove, IL, USA M. H. Scheetz Department of Pharmacy, Northwestern Memorial Hospital, Chicago, IL, USA
randomized trial for the treatment of patients with COVID-19. Hydroxychloroquine (HCQ) is an agent available in an oral formulation with in vitro activity against SARS-CoV-2 that has been suggested as a potential agent. Unfortunately, results of randomized trials evaluating HCQ as treatment against a control group are lacking, and little is known about its pharmacokinetic/pharmacodynamic (PK/PD) profile against SARS-CoV-2. The objective of this review was to describe the current understanding of the PK/PD and dose selection of HCQ against SARS-CoV-2, discuss knowledge gaps, and identify future studies that are needed to M. H. Scheetz Department of Pharmacology, College of Graduate Studies, Midwestern University, Downers Grove, IL, USA S. Goswami InsightRX, San Francisco, CA, USA J. M. Pogue Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, MI, USA M. J. Rybak Division of Infectious Diseases, Department of Medicine, Wayne State University, Detroit, MI, USA M. J. Rybak Department of Pharmacy, Detroit Medical Center, Detroit, MI, USA
Infect Dis Ther
optimize the efficacy and safety of treatments against COVID-19.
Keywords: COVID-19; Hydroxychloroquine; Pharmacodynamics; Pharmacokinetics Key Summary Points Information regarding pharmacokinetic/ pharmacodynamic (PK/PD) properties of hydroxychloroquine (HCQ) against SARSCoV-2 are lacking. This review describes the current understanding of PK/PD properties and dose selection of HCQ against SARS-CoV2. This review also discusses knowledge gaps that are needed to optimize efficacy/safety of treatments against COVID-19.
INTRODUCTION The 2019 novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is responsible for coronavirus disease
Data Loading...
